Contributing Member – Ron Ternoway
Ron Ternoway has shared his experience with WM in “Trials of a Wally”. We thought we would share with the WMFC community!
Through a partnership with the American Association for Clinical Chemistry (AACC), the IWMF has added a terrific new resource to our web site–to help WM patients and caregivers better understand laboratory results…please see http://www.iwmf.com/about-wm/blood-tests.
This resource is Lab… Continue reading
Author(s): Paludo J, Ansell SM
Abstract: Waldenström macroglobulinemia (WM) is a distinct clinicopathologic entity characterized by the presence of a lymphoplasmacytic lymphoma, a non-Hodgkin lymphoma, and IgM monoclonal gammopathy. WM is an indolent, uncommon… Continue reading
WMFC Member was featured in the QEII Time – The Chronicle. The article discusses the support he has received from the QEII Hematology Clinic.
The Waldenstrom’s Macroglobulinemia Foundation of Canada would like to extend a sincere thank you to Bert Visheau, a Board of Director member since 2003, for his dedication and support to the WMFC. Bert has stepped down after… Continue reading
Treatment options are limited for patients with Waldenstrom’s macroglobulinemia (WM), says Morie A. Gertz, MD. Combination therapies offer a potential solution, but the rarity of the disease is an obstacle. The disease occurs in roughly 4 patients per million, per… Continue reading
IMBRUVICA® is an oral, once-daily, single-agent therapy associated with a durable response in patients with this rare B-cell lymphoma
TORONTO, May 12, 2016 /CNW/ – Janssen Inc. announced today that Health Canada has issued… Continue reading